NOVEL OMEZA® OCM™ WOUND HEALING PLATFORM COMBINED WITH OFFLOADING IN PATIENTS WITH DIABETIC FOOT ULCERS DEMONSTRATED DRAMATIC HEALING RATES WITHIN 12 WEEKS OR LESS
LONDON, May 3, 2024 /PRNewswire/ -- Omeza®, a regenerative skincare company that develops marine-based therapies for wounds that are hard to treat, today presented final data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza® OCM™ plus offloading of weight on the affected foot achieved a 94 percent area reduction (PAR) rate in DFUs within twelve weeks, and a 62 percent PAR within four weeks. PAR is considered a surrogate endpoint of complete wound healing, with a PAR of 50 percent at four weeks in diabetic wound patients considered a strong predictor of subsequent complete healing.1
www.omezapro.com) is a skin science company dedicated to equitable access to better wound care outcomes for patients at all sites of care. The company is based in Sarasota, FL USA. Inquiries from medical and health professionals should be directed to info@omezapro.com. (PRNewsfoto/Omeza LLC)" alt="Omeza (www.omezapro.com) is a skin science company dedicated to equitable access to better wound care outcomes for patients at all sites of care. The company is based in Sarasota, FL USA. Inquiries from medical and health professionals should be directed to info@omezapro.com. (PRNewsfoto/Omeza LLC)">
Final data from the clinical trial are being presented at the 34th annual Conference of the European Wound Management Association (EWMA) May 1-3.
"Diabetic foot ulcers are one of ...
Full story available on Benzinga.com